{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T10:59:31Z","timestamp":1648724371027},"reference-count":6,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.leukres.2014.09.015","type":"journal-article","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T22:52:38Z","timestamp":1413413558000},"page":"1399-1400","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: A perspective of the SEPT9-ABL1 fusion protein"],"prefix":"10.1016","volume":"38","author":[{"given":"Tinghui","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan T.","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.09.015_bib0005","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","article-title":"Role of ABL family kinases in cancer: from leukaemia to solid tumours","volume":"13","author":"Greuber","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.leukres.2014.09.015_bib0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.leukres.2014.09.015_bib0015","first-page":"54","article-title":"Identification of a novel SEPT9-ABL1 fusion gene in a patient with T-cell prolymphocytic leukemia","volume":"3","author":"Suzuki","year":"2014","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.leukres.2014.09.015_bib0020","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.leukres.2014.08.015","article-title":"Functional analysis of the SEPT9-ABL1 chimeric fusion gene derived from T-prolymphocytic leukemia","volume":"38","author":"Kawai","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.09.015_bib0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1515\/BC.2011.072","article-title":"MLL-SEPTIN gene fusions in hematological malignancies","volume":"392","author":"Cerveira","year":"2011","journal-title":"Biol Chem"},{"key":"10.1016\/j.leukres.2014.09.015_bib0030","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00441-013-1618-6","article-title":"Septin9 is involved in T-cell development and CD8+ T-cell homeostasis","volume":"352","author":"Lassen","year":"2013","journal-title":"Cell Tissue Res"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614002975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614002975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T09:27:31Z","timestamp":1538126851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614002975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":6,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0145212614002975"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.09.015","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: A perspective of the SEPT9-ABL1 fusion protein","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}